Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Has Consensus Price Target of $27.14

Key Points

• Analysts are broadly bullish on Zevra Therapeutics: Eleven brokerages assign the stock an average “Buy” rating, with a consensus 12-month price target of $27.14 versus a recent price of $11.08.
• The company exceeded quarterly expectations, reporting $0.25 in EPS and $39.66 million in revenue, ahead of consensus estimates of $0.11 EPS and $33.88 million in revenue.
• Institutional ownership stands at 35.03%, with several investors recently initiating or expanding positions; however, a company director sold 12,300 shares, reducing his stake by 87.23%.

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have earned an average recommendation of "Buy" from the eleven brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $27.14.

Several brokerages recently commented on ZVRA. Weiss Ratings reiterated a "hold (c)" rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. Wall Street Zen upgraded shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Sunday, July 12th. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating for the company in a report on Monday, July 27th. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. Finally, Guggenheim reduced their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Friday, August 7th.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $11.08 on Thursday. The stock's 50 day moving average price is $11.45 and its 200 day moving average price is $11.36. Zevra Therapeutics has a 1-year low of $8.01 and a 1-year high of $15.03. The company has a market cap of $657.93 million, a PE ratio of 12.04 and a beta of 0.98.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analysts' expectations of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, equities research analysts anticipate that Zevra Therapeutics will post 0.72 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Corey Watton sold 12,300 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the transaction, the director directly owned 1,800 shares of the company's stock, valued at $20,250. This trade represents a 87.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.70% of the stock is owned by insiders.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC purchased a new position in shares of Zevra Therapeutics in the second quarter valued at $28,000. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Zevra Therapeutics in the 4th quarter worth about $53,000. Tidal Investments LLC acquired a new stake in Zevra Therapeutics in the 2nd quarter valued at about $150,000. DGS Capital Management LLC acquired a new stake in Zevra Therapeutics in the 4th quarter valued at about $133,000. Finally, WINTON GROUP Ltd increased its holdings in Zevra Therapeutics by 49.0% during the 2nd quarter. WINTON GROUP Ltd now owns 24,335 shares of the company's stock valued at $349,000 after acquiring an additional 8,001 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra's lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.